Host Immune Response to Novel RNA COVID-19 Vaccination

NCT04784689 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-05-25

No results posted yet for this study

Summary

To determine the antibody response level in patients with cancer to the COVID-19 vaccination.

Conditions

Interventions

BIOLOGICAL

COVID-19 Vaccine

COVID-19 Vaccine

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Dimpy Shah, MD PhD · University of Texas Health Science Center San Antonio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-24
Primary Completion
2022-05-18
Completion
2022-05-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04784689 on ClinicalTrials.gov